China's Kossel Medtech raises $60M Series C to scale interventional devices
What's the deal? Kossel Medtech, a Suzhou-based medical device maker, has closed a 400 million CNY (about $60 million) Series C round. Shenzhen Capital Group and Jinhe CapitalDealroom has a profile for this one. Try Dealroom → co-led, with Frontier InvestmentDealroom has a profile for this one. Try Dealroom → and Chuangjing CapitalDealroom has a profile for this one. Try Dealroom → joining.
Who else backed it? Existing investors — including SuchuangtouDealroom has a profile for this one. Try Dealroom → (backed by the social security fund), Sugaoxin Financial Holdings, Sugaoxin Co., and Yuein Medical Fund — added to their stakes above their original allocations.
What's the endgame? Kossel Medtech plans to use the money to expand production capacity and advance research on its core products. Those span peripheral intervention, coronary intervention, and cardiac electrophysiology, along with global regulatory registration.
Why now? The company is pushing to register its devices in markets beyond China, a step that requires both manufacturing scale and clinical approvals. This round funds that expansion.
The signal: The backing from state-linked funds and repeat investors points to sustained appetite for Chinese interventional cardiology firms aiming to compete globally. Kossel Medtech's raise reflects a broader push among domestic device makers to move from local supply toward international markets.
Image credit: Generated with Gemini
